SCHEMBL7259173

SCHEMBL7259173

COc1ccc(C=CS(=O)(=O)Nc2ccc(OC)c(F)c2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
LMNA P02545 2/20 0.62
PTGES2 Q9H7Z7 1/20 0.49
GHSR Q92847 1/20 0.47
TUBB1 Q9H4B7 5/20 0.47
HTT P42858 2/20 0.46
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.46
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44
TUBA3C P0DPH7 2/20 0.44
TUBA1B P68363 2/20 0.44
TUBA4A P68366 2/20 0.44
TUBB4B P68371 2/20 0.44
TUBB3 Q13509 2/20 0.44
TUBB2A Q13885 2/20 0.44
TUBB8 Q3ZCM7 2/20 0.44
TUBA3E Q6PEY2 2/20 0.44
TUBA1A Q71U36 2/20 0.44
TUBA1C Q9BQE3 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL826464 0.84 ALDH1A1 (0.85) ALDH1A1LMNAPTGES2TUBB1HTT
SCHEMBL826463 0.84 ALDH1A1 (0.85) ALDH1A1LMNAPTGES2TUBB1HTT
SCHEMBL1122229 0.83 ALDH1A1 (0.74) ALDH1A1LMNAPTGES2HTTKMT2A
SCHEMBL1122677 0.79 ALDH1A1 (0.68) ALDH1A1LMNAPTGES2TUBB1HTT
SCHEMBL1123111 0.78 BACE1 (0.47) ALDH1A1LMNAGHSRTUBB1MAPT
SCHEMBL827806 0.78 ALDH1A1 (0.74) ALDH1A1LMNAPTGES2KMT2APKM
SCHEMBL5622505 0.78 CYP19A1 (0.64) ALDH1A1LMNAHTTKMT2APKM
SCHEMBL1122440 0.78 ALDH1A1 (0.58) ALDH1A1LMNAPTGES2TUBB1HTT
SCHEMBL827807 0.78 ALDH1A1 (0.74) ALDH1A1LMNAPTGES2KMT2APKM
SCHEMBL826539 0.77 ALDH1A1 (1.00) ALDH1A1LMNAPTGES2GHSRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6646009-B2 Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation Temple University — Of Commonwealth System of Higher Education 2003-11-11 US disclosed
US-20020165412-A1 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof ONCONOVA THERAPEUTICS, INC. 2002-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165412-A1 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof HCCS, NAT1, ARSA ALDH1A1 678/4885LMNA 3112/4885PTGES2 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.